Axogen, Inc. · NASDAQ:AXGN
Axogen — Shareholder Meeting (August 2012)
22 slides from Axogen's shareholder meeting presentation, Aug 30, 2012
Slide 1: Shareholder Meeting
Shareholder Meeting August 30, 2012 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This Presentation contains “forward-looking” statements results to differ materially from those set forth in this as defined in the Private Securities Litigation Reform Act presentation or any related materials. Forward-looking of 1995. These statements are based on management’
Slide 3: Highlights Since Last Meeting
Highlights Since Last Meeting • AxoGen is a regenerative medicine technology company Revenues offering a complete portfolio of surgical solutions for $4.9 Million 2011 peripheral nerve repair and reconstruction: $2.0 Million Q2 2012 $3.7 Million Q1 & Q2 2012 Q2 Gross Margin 75% Stock Price High of $
Slide 4: Causes & Incidence of Nerve Injuries
Causes & Incidence of Nerve Injuries Injuries vary and can affect outcomes AxoGen Technology Causes of Peripheral Nerve Injuries include Applications • Power tool / saw accidents • Motor vehicle accidents • Battle field injuries • Carpal tunnel Erb’s Palsy Lacerated Hand • Lacerations • Dislocations
Slide 5: Peripheral Nerve Injuries
Peripheral Nerve Injuries Guide Natural Nerve Regeneration Process Peripheral nerves provide the pathways for both motor and sensory signals between the central nervous system and target organs, regulating movement and sensation • Successful nerve regeneration depends on • Structure and guidance: pr
Slide 6: Autograft Characteristics
Autograft Characteristics Patient sacrifices nerve function at the donor site • Traditional “Gold Standard” for peripheral nerve repair • Requires secondary surgery on patient to harvest healthy donor nerve (typically the sural nerve) • Patient loses function and sensation at the nerve harvest site
Slide 7: Hollow-Tube Conduit
Hollow-Tube Conduit • Hollow-tube used to bridge nerve gaps and provide gross direction for re- growth • Lacks internal structure; reliant on fibrin bridge to support regenerating nerve fibers • Use limited to small gaps; 34%-57% failure rate >5mm gaps1 • Reliability of repair diminishes at longer g
Slide 8: AxoGen's Innovative Solutions
AxoGen’s Innovative Solutions Regenerative medicine Avance® Nerve Graft is a decellularized products typically consist of and sterile ECM scaffold processed from human peripheral nerve tissue • Scaffold: The structure of ExtraCellular Matrix (ECM) to support the cells and/or provide the architecture
Slide 9: AxoGen: Complete Nerve Repair Portfolio
AxoGen: Complete Nerve Repair Portfolio mm gap • Allograft tissue bridges 70 severed nerve 65 • Shortest lengths priced 60 competitively to conduits, 55 provides clinical 50 advantage 45 40 35 • Wraps and protects injured 30 nerves 25 • Reinforces coaptation 20 15 10 • Bridges gaps up to 5mm 5 • Coa
Slide 10: Avance Nerve Graft Clinical Study Results
Avance® Nerve Graft Clinical Study Results Injuries Achieving Meaningful Treatment response by Treatment response based on Recovery* injury/gap length** time from injury to repair** 100% 98% 89% 98% 100% 93% 85% 85% 85% 85% 86% 77% Largest multi-center study in peripheral nerve reconstruction • Open
Slide 11: Study Results Compare Favorably to Other Repairs
Study Results Compare Favorably to Other Repairs Comparison to Historical Reference Literature Autograft vs. Avance Motor Study Nerve Injury Types Test Article Positive Recovery Outcomes in Mixed and Outcomes* Motor Nerves 100 % Successful Recovery AxoGen Study 78% Findings Sensory, Mixed and Avance
Slide 12: Additional Clinical Data in Development
Additional Clinical Data in Development Traumatic Injuries • RANGER – Avance Observational Registry • Current Enrollment: 215 • Next Data Tranche: Nov 2012 • RECON – Pivotal Study with Avance® Nerve Graft • Study Initiation: Q1 2013 Prostatectomy Nerve Grafting Pilot • Urology Technical Feasibil
Slide 13: Commercialization & Market Development
Commercialization & Market Development Surgeons: Change the standard of care through data, awareness & education • Awareness of growing body of clinical information • Publications • Brooks et al Journal of Microsurgery (RANGER) • Ducic et al Annals of Plastic Surgery • Karabekmez et al Hand • Clin
Slide 14: AxoGen exhibited at 34 surgical conferences in the last 12 months
AxoGen exhibited at 34 surgical conferences in the last 12 months * Proudly provided by AxoGen *WWP/ASSH promotion is sponsored by AxoGen, which is solely responsible for its fulfillment. The ‘Wounded Warrior Project’ (WWP) name and logo is used by permission. WWP is the benefiting organization. Mor
Slide 15: Commercialization & Market Development
Commercialization & Market Development Surgeons: Change the standard of care through data, awareness & education • Surgeon Educational Podium Presentations (US & OUS) • American Association of Hand • American Society of Peripheral • American Society for Surgery Surgery Nerve of the Hand • American
Slide 16: Commercialization & Market Development
Commercialization & Market Development Patients: Educate & empower the patient • Patient Education • AboutNerve.Com • Patient Stories • Understanding patient perspective through long term patient outcomes & recovery journeys, 3+ years data • Meet patients & their families – Frankie, Edward, Michae
Slide 17: Sales Team
Sales Team Provide a professional consultative sales approach to educate surgeons and change treatment algorithms • Primary focus is the hand or plastic surgeon • Hospital Purchasing Administration • Tissue Bank • OR Coordinators / Nursing • Expanded from 5 to 16 direct sales associates; maintained
Slide 18: Strong, Consistent Revenue Growth
Strong, Consistent Revenues Revenue Growth $4.8 $3.7 $3.0 60% Growth from 2010 to 2011 $2.0 $1.2 64% 2Q11compared to 2Q12 2Q11 2Q12 2010 2011 Year-to-Date 2012 18
Slide 19: Capital Structure: Investors
Capital Structure: Investors Simple flat cap structure and experienced investors (DeNovo Ventures, Cardinal Partners, AMV Partners, Springboard Capital, ATEL Ventures & LecTec shareholders) Common Stock Outstanding 11,104,039 shares Common Stock Option 2,071,446 shares Common Stock Warrant 89,686 sh
Slide 20: AXGN Share Price Performance
AXGN Share Price Performance $5.00 +43% +11% 80,000 Share price 70,000 Year-to-date $4.00 performance since performance as of 10.01.11 60,000 08.24.12 50,000 $3.00 40,000 $2.00 30,000 20,000 $1.00 10,000 $0.00 - Sep-11 Nov-11 Jan-12 Mar-12 May-12 Jul-12 Volume Price 20
Slide 21: AXGN Volume at Price Levels
AXGN Volume at Price Levels 300,000 250,000 $3.00 200,000 Share price support level 150,000 100,000 50,000 - $2.50 - $2.75 $2.75 - $3.00 $3.00 - $3.25 $3.25 - $3.50 $3.50 - $3.75 $3.75 - $4.00 21
Slide 22: Thank You Q & A
Thank You Q&A Stock Symbol “AXGN” InvestorRelations@AxoGenInc.com 22